Tesevatinib: Clinical Trials

3 trials of Tesevatinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 3 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Completed 2, Terminated 1
Phase 22Completed 1, Terminated 1

Follow Tesevatinib: new trials by email Literature Review of Tesevatinib trials Research Report on Tesevatinib

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Tesevatinib - Polycystic Kidney, Autosomal Recessive
Phase 1CompletedKadmon Corporation, LLC102017-08-242022-05-11
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Tesevatinib, Trastuzumab - HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain
Phase 1 / Phase 2TerminatedKadmon Corporation, LLC172014-05-012022-04-27
A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Tesevatinib - Polycystic Kidney, Autosomal Dominant
Phase 1 / Phase 2CompletedKadmon, a Sanofi Company692012-10-112022-11-08

Conditions studied

Brain Neoplasms (1)  ·  Polycystic Kidney Diseases (1)  ·  Polycystic Kidney, Autosomal Dominant (1)  ·  Polycystic Kidney, Autosomal Recessive (1)

Sponsors

Kadmon Corporation, LLC (2)  ·  Kadmon, a Sanofi Company (1)

Countries

United States (3)